Dr Gregory Barness from Mayo clinic, one of the most respected medical clinics in the world, published that ECP has success rate of 95%.
- Mayo clinic is now actively and enthusiastically pursuing ECP therapy for their patients.
- The Mayo Physicians concluded that ECP is a safe and effective method for treating angina, even in patients for whom surgery and angioplasty are not suitable. So we can use ECP therapy as a FIRST LINE treatment for Coronary Artery Disease.
JOHN HOPKINS UNIVERSITY MEDICAL SCHOOL studied the effect of ECP on patients who had previously failed to respond to surgery, angioplasty and maximum medication therapy.
Johns Hopkins Hospital, Baltimore, Maryland among the pioneer on ECP research and facility.
Following ECP, all of the patients showed significant improvement in their cardiac function. As a result, the researchers called for an increase in the Availability of ECP therapy across the country.
The journal of the American college of cardiology published an article in June of 1999, compiling data from the MUST-ECP that is Mulitcenter study on this treatment method
Seven prestigious university and heart centers participated in this study.
1. Columbia Presbyterian medical center, Columbia University (New York)
2. Moffit-long Hospital, University of California at San Francisco)
3. Yale University School of Medicine (New Haven)
4. Beth Israel Deaconess Medical Center, Harvard University
5.Grant/Riverside Methodist Hospitals(Columbus,OH)
6. Presbyterian University Hospital, University of Pittsburgh
7. Loyola University Medical Center (Maywood, IL)
139 patients suffering from angina, coronary heart disease with positive stress test were selected for this study.
The patients were randomly assigned to two groups.
The first group received actual (real) ECP treatment.
And the second group received “Sham” or placebo treatment. (No treatment at all).
l It is the first double blinded study to show that ECP is effective.
l There are now more blinded studies published on ECP than there are for Bypass Surgery, angioplasty and stents combined.
Dr Lawson and associates found that 64% of the patients five years after ECP treatment did not experience any further major heart events and did not require any additional angioplasty or heart surgery.
Dr John Gorcsan III from the University of Pittsburgh, recently presented evidence at the 49th Scientific Session of the American College of Cardiology, which showed that ECP significantly improves Congestive Heart Failure. In the year 2002, FDA USA approved ECP for congestive heart failure.
Research by the university showed ECP has significant results for coronary artery disease.
Find out what thousands of heart disease sufferers have already discovered. They are “living again,” thanks to ECP.
Thallium scan show improvement after ECP. Thallous chloride (201Tl) useful in myocardial perfusion imaging for the diagnosis and localization of myocardial infarction.
It may also be useful in conjunction with exercise stress testing as an adjunct in the diagnosis of ischemic heart disease (atherosclerotic coronary artery disease).
ECP Clinical Research
Researchers at Harvard University conducted experiments with counterpulsation in the 1950s, demonstrating that this technique markedly reduces the workload, and thus oxygen consumption, of the left ventricle. This basic effect has been demonstrated over the past forty years in both animal experiments and in human patients. The clinical benefits of external counterpulsation were not consistently achieved in early studies because the equipment used at the time lacked some of the features found in the current ECP systems, such as the computerized electrocardiographic gating, which makes sequential cuff inflation possible. Thanks to computer technology.
Among other research are MUST-ECP trial published in the Journal of the American College of Cardiology (JACC), International ECP Patient Registry data and The PEECH Trial
There are also some brief research summary in few international conference.
As the technology improved, however, it became apparent that both internal (i.e., intra-aortic balloon pumping) and external forms of counterpulsation were capable of improving survival in patients with cardiogenic shock following myocardial infarction. Later, in the 1980s, Dr. Zheng and colleagues in China reported on their extensive experience in treating angina using the newly developed “enhanced” or sequential, inflating ECP device that incorporated a third cuff for the buttocks. Not only did a course of treatment with the ECP system reduce the frequency and severity of anginal symptoms during normal daily functions and during exercise, but the improvements were sustained for years after therapy.
These results prompted a group of investigators at the State University of New York (SUNY) at Stony Brook to undertake a number of open label studies with the ECP system between 1989 and 1996 to reproduce the Chinese results, using both objective and subjective endpoints.
These studies, though open and nonrandomized, showed statistical improvement in exercise tolerance by patients as evidenced by thallium-stress testing and partial or complete resolution of coronary perfusion defects as evidenced by radionuclide imaging studies. All of these results have been reported in medical literature and support the assertion that ECP therapy is an effective and durable treatment for patients suffering from chronic angina pectoris.